17. Invasive Fungal Infections in Critical Illness

Quick Recap

Infectious Diseases System, new protocol. Companion to Antimicrobial Stewardship Programs and Antimicrobial Dosing & TDM in Critical Illness (both Infectious Diseases System) — addresses invasive Candida and Aspergillus infections specifically in non-neutropenic, non-transplant critically ill patients, a population where recent guidance has moved sharply against a once-common empiric-therapy reflex.

1. Definition

Invasive candidiasis and invasive pulmonary aspergillosis (IPA) are increasingly recognized in immune-competent, non-neutropenic, non-transplant ICU patients, not just the classically immunocompromised populations these diseases were historically associated with. A genuinely important framing this protocol emphasizes upfront: much of the foundational treatment evidence for IPA specifically comes from hematologic malignancy/transplant populations, leaving a real evidence gap for ICU patients without those specific risk factors — recommendations for this population are frequently extrapolated rather than directly evidence-based.

2. A Genuine, Guideline-Level Reversal of Common Practice — Against Routine Empiric Antifungal Therapy

The 2024 American Thoracic Society clinical practice guideline made a conditional recommendation AGAINST routine administration of prophylactic or empiric antifungal therapy targeting Candida species in critically ill patients without neutropenia or a history of transplant — explicitly based on low-quality evidence, using GRADE methodology. This protocol treats this as a genuinely important corrective to a once-common ICU reflex: broad empiric antifungal coverage "just in case" for a sick, antibiotic-exposed patient is not supported by current guidance, and should be reserved for clearly defined high-risk scenarios rather than applied broadly across the ICU.

A practical tool for identifying who actually warrants empiric therapy: the Candida score-based strategy — one prospective cohort study used a Candida score ≥3 (incorporating multifocal Candida colonization) combined with uncontrolled sepsis despite broad-spectrum antibiotics and no proven bacterial infection as the trigger for empiric echinocandin therapy, rather than treating broadly based on generic ICU risk alone.

3. Diagnostics — Genuine Tradeoffs Between Available Tests

Beta-D-Glucan (BDG)

• A non-culture-based fungal cell wall component assay, useful across both candidiasis and aspergillosis
• A direct comparative study found BDG more SENSITIVE than galactomannan for aspergillosis (97% vs. 82%) but LESS SPECIFIC (81% vs. 49% specificity for galactomannan, i.e., galactomannan is more specific) — a genuine tradeoff: BDG catches more true cases but also generates more false positives; neither test should be used in isolation without integrating the clinical picture
• A prospective ICU cohort study examining BDG's added diagnostic value specifically in critically ill patients found its actual benefit had "not been verified" prior to that study — this protocol treats BDG as a useful adjunct, not a standalone diagnostic tool with unambiguous, independently-established value in this specific population

Galactomannan

• The most widely studied non-culture assay specifically for invasive pulmonary aspergillosis, with sensitivity 67-100% and specificity 86-100% across studies (wide ranges reflecting genuine population/technique variability) — the only FDA-approved assay is the Platelia Aspergillus EIA

4. Treatment — Candidiasis

Echinocandins remain first-line initial therapy for invasive candidiasis, working by blocking beta-1,3-glucan synthase (an essential fungal cell wall component) — generally well tolerated with a favorable safety profile. Transition to oral azole therapy is appropriate once the patient is clinically stable and the organism's susceptibility is confirmed.

Rezafungin: a newly FDA-approved echinocandin with a remarkable extended half-life of approximately 133 hours, enabling once-weekly dosing — a genuinely practical advantage, reducing the need for repeated central line access (and the associated CLABSI risk this creates, cross-reference CLABSI/VAP/CAUTI Prevention Bundles, Infectious Diseases System) and achieving higher early plasma concentrations. A pooled analysis of two RCTs (phase 2 STRIVE, phase 3 ReSTORE) found rezafungin noninferior to caspofungin, with a suggested early treatment benefit attributable specifically to its dosing regimen.

A well-established, genuinely important process finding: a strong correlation exists between time to antifungal therapy administration and outcome — once empiric therapy is genuinely indicated (per the risk-stratified approach above, not routine broad application), delay itself carries real cost.

5. Treatment — Invasive Pulmonary Aspergillosis

The 2024 ATS guideline made a conditional recommendation for EITHER initial combination therapy (mold-active triazole plus an echinocandin) OR mold-active triazole monotherapy for proven/probable IPA — again explicitly based on low-quality evidence. This is a genuinely unresolved choice, not a matter of one approach being clearly superior; the guideline itself frames this as conditional given the underlying evidentiary limitations. Voriconazole remains a standard first-line choice per prior IDSA guidance, with combination triazole-echinocandin therapy more commonly reserved for salvage treatment when initial monotherapy proves ineffective.

A specific, real-world Chinese ICU retrospective comparison (voriconazole alone vs. caspofungin alone vs. combination, n=151) examined clinical efficacy, adverse drug reactions, and all-cause mortality — illustrating that direct ICU-specific comparative data, while still emerging, is beginning to accumulate to help close the extrapolation gap noted in Section 1.

6. Practical Synthesis

1. Do not routinely start empiric or prophylactic antifungal therapy in non-neutropenic, non-transplant critically ill patients — current guidance conditionally recommends against this, based on the low-quality-evidence GRADE assessment
2. Use a risk-stratified trigger (e.g., Candida score ≥3 with uncontrolled sepsis despite antibiotics and no bacterial source found) to identify the specific patients where empiric therapy is genuinely warranted, rather than broad application
3. Interpret BDG and galactomannan as complementary, imperfect tools — BDG's higher sensitivity/lower specificity versus galactomannan's higher specificity/more variable sensitivity means neither should stand alone without clinical correlation
4. Echinocandins remain first-line for candidiasis; rezafungin's once-weekly dosing is a genuinely practical option worth considering, particularly where reducing central line access frequency is a priority
5. For IPA, recognize that either triazole monotherapy or triazole-echinocandin combination is a reasonable, guideline-endorsed choice — this is a genuinely open question, not one with a clearly superior answer
6. Once therapy is genuinely indicated, don't delay — time-to-therapy correlates with outcome

7. Consultation Matrix

8. Documentation & Medicolegal Checklist

• Specific risk-stratification criteria met (e.g., Candida score, sepsis pattern) documented before empiric antifungal initiation
• Diagnostic test results (BDG, galactomannan) interpreted alongside, not instead of, clinical picture, with this integration documented
• Rationale for triazole monotherapy vs. combination therapy in IPA documented, given the genuinely open nature of this choice

9. Key Guidelines

• 2024 American Thoracic Society Clinical Practice Guideline: Treatment of Invasive Pulmonary Aspergillosis and Preventive/Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients
• 2025 ECMM/ISHAM/ASM global guideline for invasive candidiasis
• 2016 IDSA recommendations (prior standard, still informing specific agent selection within the 2024 ATS framework)

10. Landmark Evidence

11. Controversies

• The 2024 ATS guideline's recommendations on both key questions (empiric Candida therapy and IPA treatment choice) are explicitly "conditional" and based on "low-quality evidence" — this protocol treats this honestly as the current best available guidance while being clear it does not represent high-certainty, definitively-resolved practice.
• Most IPA treatment evidence originates from hematologic malignancy/transplant populations, not ICU patients specifically — a genuine, acknowledged extrapolation gap this protocol does not paper over, even as ICU-specific comparative data slowly accumulates.
• BDG's real-world diagnostic value specifically in ICU patients was, per at least one dedicated study, genuinely unverified prior to that study — a reminder that a biologically plausible, widely-used test can still have an incompletely established evidence base in a specific population.

12. References

1. Kritikos A, Evans SE, Peghin M, et al. Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024.
2. Invasive Candidiasis in 2026: Harmonizing Global and US Guidance in an Era of Diagnostic and Stewardship Complexity. Contagion Live, 2026.
3. The added value of (1,3)-β-D-glucan for the diagnosis of Invasive Candidiasis in ICU patients: a prospective cohort study. Ann Intensive Care. 2024.
4. Diagnosis and management of invasive fungal diseases in non-neutropenic ICU patients, with focus on candidiasis and aspergillosis: a comprehensive review. 2024.
5. Thompson GR 3rd, et al. Pooled analysis of Rezafungin vs. Caspofungin (STRIVE and ReSTORE trials). 2023.
6. Candidemia in Adult Patients in the ICU: A Reappraisal of Susceptibility Testing and Antifungal Therapy. Ann Pharmacother. 2024;58(3):305-321.
7. Empirical antifungal therapy with an echinocandin in critically-ill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU. 2014.
8. Efficacy and safety of voriconazole and caspofungin for the treatment of invasive pulmonary aspergillosis in critically ill patients in China. 2024.

See also: Antimicrobial Stewardship Programs (Infectious Diseases System) for the broader stewardship framework this protocol's "against routine empiric therapy" recommendation exemplifies; Antimicrobial Dosing & TDM in Critical Illness (Infectious Diseases System) for the general dosing framework; Multidrug-Resistant Organism Management (Infectious Diseases System) for the bacterial-resistance counterpart to this fungal-specific protocol; Febrile Neutropenia (Hematology System) for the genuinely different, higher-risk population where empiric antifungal therapy IS more readily indicated.